<?xml version="1.0" encoding="UTF-8"?> 
<DIV8 N="4.116" TYPE="SECTION" hierarchy_metadata="{&quot;path&quot;:&quot;/on/_SUBSTITUTE_DATE_/title-38/section-4.116&quot;,&quot;citation&quot;:&quot;38 CFR 4.116&quot;}">
<HEAD>Â§ 4.116 Schedule of ratingsâgynecological conditions and disorders of the breast.</HEAD>
<DIV width="100%"><DIV class="gpotbl_div"><TABLE border="1" cellpadding="1" cellspacing="1" class="gpotbl_table" frame="void" width="100%"><TR><TH class="gpotbl_colhed" scope="col">
</TH><TH class="gpotbl_colhed" scope="col">Rating
</TH></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em"><E T="02">Note 1:</E> Natural menopause, primary amenorrhea, and pregnancy and childbirth are not disabilities for rating purposes. Chronic residuals of medical or surgical complications of pregnancy may be disabilities for rating purposes.
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em"><E T="02">Note 2:</E> When evaluating any claim involving loss or loss of use of one or more creative organs or anatomical loss of one or both breasts, refer to Â§ 3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which potentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitlement to special monthly compensation.
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row">7610 Vulva or clitoris, disease or injury of (including vulvovaginitis)
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row">7611 Vagina, disease or injury of.
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row">7612 Cervix, disease or injury of.
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row">7613 Uterus, disease, injury, or adhesions of.
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row">7614 Fallopian tube, disease, injury, or adhesions of (including pelvic inflammatory disease (PID)).
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row">7615 Ovary, disease, injury, or adhesions of.
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row">General Rating Formula for Disease, Injury, or Adhesions of Female Reproductive Organs (diagnostic codes 7610 through 7615):
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">Symptoms not controlled by continuous treatment</TD><TD align="right" class="gpotbl_cell">30
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">Symptoms that require continuous treatment</TD><TD align="right" class="gpotbl_cell">10
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">Symptoms that do not require continuous treatment</TD><TD align="right" class="gpotbl_cell">0
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em"><E T="02">Note:</E> For the purpose of VA disability evaluation, a disease, injury, or adhesions of the ovaries resulting in ovarian dysfunction affecting the menstrual cycle, such as dysmenorrhea and secondary amenorrhea, shall be rated under diagnostic code 7615</TD><TD align="right" class="gpotbl_cell">
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row">7617 Uterus and both ovaries, removal of, complete:
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">For three months after removal</TD><TD align="right" class="gpotbl_cell">
<sup>1</sup> 100
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">Thereafter</TD><TD align="right" class="gpotbl_cell">
<sup>1</sup> 50
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row">7618 Uterus, removal of, including corpus:
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">For three months after removal</TD><TD align="right" class="gpotbl_cell">
<sup>1</sup> 100
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">Thereafter</TD><TD align="right" class="gpotbl_cell">
<sup>1</sup> 30
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row">7619 Ovary, removal of:
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">For three months after removal</TD><TD align="right" class="gpotbl_cell">
<sup>1</sup> 100
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">Thereafter:
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 8em">Complete removal of both ovaries</TD><TD align="right" class="gpotbl_cell">
<sup>1</sup> 30
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 8em">Removal of one with or without partial removal of the other</TD><TD align="right" class="gpotbl_cell">
<sup>1</sup> 0
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em"><E T="02">Note:</E> In cases of the removal of one ovary as the result of a service-connected injury or disease, with the absence or nonfunctioning of a second ovary unrelated to service, an evaluation of 30 percent will be assigned for the service-connected ovarian loss
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row">7620 Ovaries, atrophy of both, complete</TD><TD align="right" class="gpotbl_cell">
<sup>1</sup> 20
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row">7621 Complete or incomplete pelvic organ prolapse due to injury, disease, or surgical complications of pregnancy</TD><TD align="right" class="gpotbl_cell">10
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em"><E T="02">Note:</E> Pelvic organ prolapse occurs when a pelvic organ such as bladder, urethra, uterus, vagina, small bowel, or rectum drops (prolapse) from its normal place in the abdomen. Conditions associated with pelvic organ prolapse include: uterine or vaginal vault prolapse, cystocele, urethrocele, rectocele, enterocele, or any combination thereof. Evaluate pelvic organ prolapse under DC 7621. Evaluate separately any genitourinary, digestive, or skin symptoms under the appropriate diagnostic code(s) and combine all evaluations with the 10 percent evaluation under DC 7621
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row">7624 Fistula, rectovaginal:
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">Vaginal fecal leakage at least once a day requiring wearing of pad</TD><TD align="right" class="gpotbl_cell">100
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">Vaginal fecal leakage four or more times per week, but less than daily, requiring wearing of pad</TD><TD align="right" class="gpotbl_cell">60
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">Vaginal fecal leakage one to three times per week requiring wearing of pad</TD><TD align="right" class="gpotbl_cell">30
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">Vaginal fecal leakage less than once a week</TD><TD align="right" class="gpotbl_cell">10
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">Without leakage</TD><TD align="right" class="gpotbl_cell">0
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row">7625 Fistula, urethrovaginal:
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">Multiple urethrovaginal fistulae</TD><TD align="right" class="gpotbl_cell">100
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">Requiring the use of an appliance or the wearing of absorbent materials which must be changed more than four times per day</TD><TD align="right" class="gpotbl_cell">60
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">Requiring the wearing of absorbent materials which must be changed two to four times per day</TD><TD align="right" class="gpotbl_cell">40
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">Requiring the wearing of absorbent materials which must be changed less than two times per day</TD><TD align="right" class="gpotbl_cell">20
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row">7626 Breast, surgery of:
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">Following radical mastectomy:
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 8em">Both</TD><TD align="right" class="gpotbl_cell">
<sup>1</sup>80
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 8em">One</TD><TD align="right" class="gpotbl_cell">
<sup>1</sup>50
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">Following modified radical mastectomy:
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 8em">Both</TD><TD align="right" class="gpotbl_cell">
<sup>1</sup>60
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 8em">One</TD><TD align="right" class="gpotbl_cell">
<sup>1</sup>40
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">Following simple mastectomy or wide local excision with significant alteration of size or form:
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 8em">Both</TD><TD align="right" class="gpotbl_cell">
<sup>1</sup>50
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 8em">One</TD><TD align="right" class="gpotbl_cell">
<sup>1</sup>30
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">Following wide local excision without significant alteration of size or form:
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 8em">Both or one</TD><TD align="right" class="gpotbl_cell">0
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em"><E T="02">Note:</E> For VA purposes:
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 8em">(1) <E T="03">Radical mastectomy</E> means removal of the entire breast, underlying pectoral muscles, and regional lymph nodes up to the coracoclavicular ligament.
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 8em">(2) <E T="03">Modified radical mastectomy</E> means removal of the entire breast and axillary lymph nodes (in continuity with the breast). Pectoral muscles are left intact.
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 8em">(3) <E T="03">Simple (or total) mastectomy</E> means removal of all of the breast tissue, nipple, and a small portion of the overlying skin, but lymph nodes and muscles are left intact.
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 8em">(4) <E T="03">Wide local excision</E> (including partial mastectomy, lumpectomy, tylectomy, segmentectomy, and quadrantectomy) means removal of a portion of the breast tissue.
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row">7627 Malignant neoplasms of gynecological system</TD><TD align="right" class="gpotbl_cell">100
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em"><E T="02">Note:</E> A rating of 100 percent shall continue beyond the cessation of any surgical, radiation, antineoplastic chemotherapy or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of Â§ 3.105(e) of this chapter. Rate chronic residuals to include scars, lymphedema, disfigurement, and/or other impairment of function under the appropriate diagnostic code(s) within the appropriate body system
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row">7628 Benign neoplasms of gynecological system. Rate chronic residuals to include scars, lymphedema, disfigurement, and/or other impairment of function under the appropriate diagnostic code(s) within the appropriate body system
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row">7629 Endometriosis:
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">Lesions involving bowel or bladder confirmed by laparoscopy, pelvic pain or heavy or irregular bleeding not controlled by treatment, and bowel or bladder symptoms</TD><TD align="right" class="gpotbl_cell">50
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">Pelvic pain or heavy or irregular bleeding not controlled by treatment</TD><TD align="right" class="gpotbl_cell">30
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em">Pelvic pain or heavy or irregular bleeding requiring continuous treatment for control</TD><TD align="right" class="gpotbl_cell">10
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em"><E T="02">Note:</E> Diagnosis of endometriosis must be substantiated by laparoscopy.
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row">7630 Malignant neoplasms of the breast</TD><TD align="right" class="gpotbl_cell">100
</TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row" style="padding-left: 4em"><E T="02">Note:</E> A rating of 100 percent shall continue beyond the cessation of any surgical, radiation, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of Â§ 3.105(e) of this chapter. Rate chronic residuals according to impairment of function due to scars, lymphedema, or disfigurement (e.g., limitation of arm, shoulder, and wrist motion, or loss of grip strength, or loss of sensation, or residuals from harvesting of muscles for reconstructive purposes), and/or under diagnostic code 7626
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row">7631 Benign neoplasms of the breast and other injuries of the breast. Rate chronic residuals according to impairment of function due to scars, lymphedema, or disfigurement (e.g., limitation of arm, shoulder, and wrist motion, or loss of grip strength, or loss of sensation, or residuals from harvesting of muscles for reconstructive purposes), and/or under diagnostic code 7626
</TD><TD align="right" class="gpotbl_cell"></TD></TR><TR><TD align="left" class="gpotbl_cell" scope="row">7632 Female sexual arousal disorder (FSAD)</TD><TD align="right" class="gpotbl_cell">
<sup>1</sup> 0
</TD></TR></TABLE></DIV><DIV class="table_foot"><P class="gpotbl_note">
<sup>1</sup> Review for entitlement to special monthly compensation under Â§ 3.350 of this chapter.</P></DIV></DIV>
<SECAUTH TYPE="N">(Authority: 38 U.S.C. 1155)
</SECAUTH>
<CITA TYPE="N">[60 FR 19855, Apr. 21, 1995, as amended at 67 FR 6874, Feb. 14, 2002; 67 FR 37695, May 30, 2002; 83 FR 15071, Apr. 9, 2018]
</CITA>
</DIV8>
